TY - JOUR
T1 - CKD, Brain Atrophy, and White Matter Lesion Volume
T2 - The Japan Prospective Studies Collaboration for Aging and Dementia
AU - Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD) Study Group
AU - Maki, Kenji
AU - Ohara, Tomoyuki
AU - Hata, Jun
AU - Shibata, Mao
AU - Hirabayashi, Naoki
AU - Honda, Takanori
AU - Sakata, Satoko
AU - Furuta, Yoshihiko
AU - Akiyama, Masato
AU - Yamasaki, Keisuke
AU - Tatewaki, Yasuko
AU - Taki, Yasuyuki
AU - Kitazono, Takanari
AU - Mikami, Tatsuya
AU - Maeda, Tetsuya
AU - Ono, Kenjiro
AU - Mimura, Masaru
AU - Nakashima, Kenji
AU - Iga, Jun ichi
AU - Takebayashi, Minoru
AU - Ninomiya, Toshiharu
AU - Nakaji, Shigeyuki
AU - Murashita, Koichi
AU - Jung, Songee
AU - Misawa, Mina
AU - Ishizuka, Naoki
AU - Akasaka, Hiroshi
AU - Terayama, Yasuo
AU - Yonezawa, Hisashi
AU - Takahashi, Junko
AU - Noguchi-Shinohara, Moeko
AU - Komatsu, Junji
AU - Shibata, Shutaro
AU - Yuki-Nozaki, Sohshi
AU - Bun, Shogyoku
AU - Niimura, Hidehito
AU - Shikimoto, Ryo
AU - Kida, Hisashi
AU - Fukada, Yasuyo
AU - Kowa, Hisanori
AU - Nakano, Toshiya
AU - Wada, Kenji
AU - Kishi, Masafumi
AU - Ozaki, Tomoki
AU - Tachibana, Ayumi
AU - Yoshino, Yuta
AU - Shu-ichi Ueno, Jun ichi Iga
AU - Ishikawa, Tomohisa
AU - Yuki, Seiji
AU - Koyama, Asuka
N1 - Funding Information:
This study was supported by the Japan Agency for Medical Research and Development ( JP22dk0207053 ) and Suntory Holdings Limited (Osaka, Japan). The funders had no role in the design of the study, the collection, analysis, and interpretation of data, or the writing of the manuscript.
Funding Information:
Kyushu University ([Epidemiology and Public Health] Toshiharu Ninomiya, Jun Hata, Mao Shibata, and Takanori Honda, [Neuropsychiatry] Tomoyuki Ohara, [Ocular Pathology and Imaging Science] Masato Akiyama); Hirosaki University (Shigeyuki Nakaji, Koichi Murashita, Tatsuya Mikami, Songee Jung, and Mina Misawa); Iwate Medical University (Tetsuya Maeda, Naoki Ishizuka, and Hiroshi Akasaka); Shonan Keiiku Hospital (Yasuo Terayama); Japanese Red Cross Morioka Hospital (Hisashi Yonezawa); Morioka Tsunagi Onsen Hospital (Junko Takahashi); Kanazawa University (Kenjiro Ono, Moeko Noguchi-Shinohara, Junji Komatsu, Shutaro Shibata, and Sohshi Yuki-Nozaki); Keio University School of Medicine (Masaru Mimura, Shogyoku Bun, Hidehito Niimura, Ryo Shikimoto, and Hisashi Kida); Matsue Medical Center (Kenji Nakashima, Yasuyo Fukada, Hisanori Kowa, and Toshiya Nakano); Kawasaki Medical School (Kenji Wada); Tottori Red Cross Hospital (Masafumi Kishi); Ehime University (Tomoki Ozaki, Ayumi Tachibana, Yuta Yoshino, Jun-ichi Iga and Shu-ichi Ueno); Kumamoto University (Minoru Takebayashi, Tomohisa Ishikawa, Seiji Yuki, Asuka Koyama, and Naoto Kajitani); Kindai University Faculty of Medicine (Mamoru Hashimoto), Osaka University Medical School (Manabu Ikeda); National Cerebral and Cardiovascular Center (Yoshihiro Kokubo); Nakamura-Gakuen University (Kazuhiro Uchida, and Midori Esaki); Tohoku University (Yasuyuki Taki, Yasuko Tatewaki, and Benjamin Thyreau); University of the Ryukyus (Koji Yonemoto); Osaka Metropolitan University Graduate School of Medicine (Hisako Yoshida); University of Tokyo (Kaori Muto, Yusuke Inoue, and Izen Ri); RIKEN Center for Integrative Medical Sciences (Yukihide Momozawa and Chikashi Terao); Hisayama Research Institute for Lifestyle Diseases (Michiaki Kubo and Yutaka Kiyohara), Kenji Maki, MD, Tomoyuki Ohara, MD, PhD, Jun Hata, MD, PhD, Mao Shibata, MD, PhD, Naoki Hirabayashi, MD, PhD, Takanori Honda, PhD, Satoko Sakata, MD, PhD, Yoshihiko Furuta, MD, PhD, Masato Akiyama, MD, PhD, Keisuke Yamasaki, MD, PhD, Yasuko Tatewaki, MD, PhD, Yasuyuki Taki, MD, PhD, Takanari Kitazono, MD, PhD, Tatsuya Mikami, MD, PhD, Tetsuya Maeda, MD, PhD, Kenjiro Ono, MD, PhD, Masaru Mimura, MD, PhD, Kenji Nakashima, MD, PhD, Jun-ichi Iga, MD, PhD, Minoru Takebayashi, MD, PhD, and Toshiharu Ninomiya, MD, PhD, on behalf of the Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD) study group, Research idea and study design: TO, KY, TMi, TMa, KO, MM, KN, JI, MT, TN; Data acquisition: TO, JH, MS, NH, TH, SS, YF, MA, YTat, YTak, TMi, TMa, KO, MM, KN, JI, MT, TN; Data analysis/interpretation: KM, TO, JH, MS, NH, TH, SS, YF, MA, KY, YTat, YTak, TK, TMi, TMa, KO, MM, KN, JI, MT, TN; Statistical analysis: KM, KY; Supervision or mentorship: TN. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. This study was supported by the Japan Agency for Medical Research and Development (JP22dk0207053) and Suntory Holdings Limited (Osaka, Japan). The funders had no role in the design of the study, the collection, analysis, and interpretation of data, or the writing of the manuscript. Dr Ninomiya reports receiving grants from Suntory Holdings Limited. The remaining authors declare that they have no relevant financial interests. We would like to gratefully acknowledge the diligent work and contributions of all researchers and investigators in the JPSC-AD Study Group. We would also like to thank the participants for the contribution of their time to the JPSC-AD study. Received July 6, 2022. Evaluated by 1 external peer reviewer, with direct editorial input from the Statistical Editor, an Associate Editor, and the Editor-in-Chief. Accepted in revised form October 26, 2022.
Funding Information:
Dr Ninomiya reports receiving grants from Suntory Holdings Limited. The remaining authors declare that they have no relevant financial interests.
Publisher Copyright:
© 2022 The Authors
PY - 2023/3
Y1 - 2023/3
N2 - Rationale & Objective: Chronic kidney disease, defined by albuminuria and/or reduced estimated glomerular filtration rate (eGFR), has been reported to be associated with brain atrophy and/or higher white matter lesion volume (WMLV), but there are few large-scale population-based studies assessing this issue. This study aimed to examine the associations between the urinary albumin-creatinine ratio (UACR) and eGFR levels and brain atrophy and WMLV in a large-scale community-dwelling older population of Japanese. Study Design: Population-based cross-sectional study. Setting & Participants: A total of 8,630 dementia-free community-dwelling Japanese aged greater than or equal to 65 years underwent brain magnetic resonance imaging scanning and screening examination of health status in 2016-2018. Exposures: UACR and eGFR levels. Outcomes: The total brain volume (TBV)-to-intracranial volume (ICV) ratio (TBV/ICV), the regional brain volume-to-TBV ratio, and the WMLV-to-ICV ratio (WMLV/ICV). Analytical Approach: The associations of UACR and eGFR levels with the TBV/ICV, the regional brain volume-to-TBV ratio, and the WMLV/ICV were assessed by using an analysis of covariance. Results: Higher UACR levels were significantly associated with lower TBV/ICV and higher geometric mean values of the WMLV/ICV (P for trend = 0.009 and <0.001, respectively). Lower eGFR levels were significantly associated with lower TBV/ICV, but not clearly associated with WMLV/ICV. In addition, higher UACR levels, but not lower eGFR, were significantly associated with lower temporal cortex volume-to-TBV ratio and lower hippocampal volume-to-TBV ratio. Limitations: Cross-sectional study, misclassification of UACR or eGFR levels, generalizability to other ethnicities and younger populations, and residual confounding factors. Conclusions: The present study demonstrated that higher UACR was associated with brain atrophy, especially in the temporal cortex and hippocampus, and with increased WMLV. These findings suggest that chronic kidney disease is involved in the progression of morphologic brain changes associated with cognitive impairment.
AB - Rationale & Objective: Chronic kidney disease, defined by albuminuria and/or reduced estimated glomerular filtration rate (eGFR), has been reported to be associated with brain atrophy and/or higher white matter lesion volume (WMLV), but there are few large-scale population-based studies assessing this issue. This study aimed to examine the associations between the urinary albumin-creatinine ratio (UACR) and eGFR levels and brain atrophy and WMLV in a large-scale community-dwelling older population of Japanese. Study Design: Population-based cross-sectional study. Setting & Participants: A total of 8,630 dementia-free community-dwelling Japanese aged greater than or equal to 65 years underwent brain magnetic resonance imaging scanning and screening examination of health status in 2016-2018. Exposures: UACR and eGFR levels. Outcomes: The total brain volume (TBV)-to-intracranial volume (ICV) ratio (TBV/ICV), the regional brain volume-to-TBV ratio, and the WMLV-to-ICV ratio (WMLV/ICV). Analytical Approach: The associations of UACR and eGFR levels with the TBV/ICV, the regional brain volume-to-TBV ratio, and the WMLV/ICV were assessed by using an analysis of covariance. Results: Higher UACR levels were significantly associated with lower TBV/ICV and higher geometric mean values of the WMLV/ICV (P for trend = 0.009 and <0.001, respectively). Lower eGFR levels were significantly associated with lower TBV/ICV, but not clearly associated with WMLV/ICV. In addition, higher UACR levels, but not lower eGFR, were significantly associated with lower temporal cortex volume-to-TBV ratio and lower hippocampal volume-to-TBV ratio. Limitations: Cross-sectional study, misclassification of UACR or eGFR levels, generalizability to other ethnicities and younger populations, and residual confounding factors. Conclusions: The present study demonstrated that higher UACR was associated with brain atrophy, especially in the temporal cortex and hippocampus, and with increased WMLV. These findings suggest that chronic kidney disease is involved in the progression of morphologic brain changes associated with cognitive impairment.
UR - http://www.scopus.com/inward/record.url?scp=85147939000&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147939000&partnerID=8YFLogxK
U2 - 10.1016/j.xkme.2022.100593
DO - 10.1016/j.xkme.2022.100593
M3 - Article
AN - SCOPUS:85147939000
SN - 2590-0595
VL - 5
JO - Kidney Medicine
JF - Kidney Medicine
IS - 3
M1 - 100593
ER -